Hyperthermic Oncology CenterBack

Oncothermia Team

1684248025656355.png

1684248025834856.png

1684248026757655.png

1684248025550980.png

1684248026621362.png

Oncothermia Team


ProFile181_500X500.png

Professor Yee Chao, MD, PhD

Dr. Yee Chao is a renowned oncologist with extensive experience in cancer treatment, specializing in hepatobiliary and gastrointestinal-related cancers. He is currently the Chief of Hyperthermia Therapy at the Central Clinic & Hospital in Taipei, Taiwan. Dr. Chao is dedicated to providing the highest quality care to his patients and is fluent in both Chinese and English. He has received numerous awards and honors for his outstanding achievements and has published over 340 medical articles in domestic and international journals. Dr. Chao's expertise in cancer treatment, combined with his compassionate and patient-centered approach, makes him a trusted and respected physician in the field of oncology.



Title:
Attending Physician of Department of Internal Medicine, Director of Hyperthermia Therapy for Tumors


Nationality:

Taiwan


Language Proficiency:
■ Chinese ■ English


Areas of Expertise: 

Cancer Treatment, Hyperthermia Therapy for Tumors, Gastric Cancer, Liver Cancer, Pancreatic Cancer, Digestive System Tumors, Colorectal Cancer, Esophageal Cancer

 

Education:

  • Ph.D. in Clinical Medicine from National Yang-Ming University (1999)

  • Bachelor of Medicine from Kaohsiung Medical University (1983)

 

Experience:

  • Attending Physician of Department of Internal Medicine, Central Clinic & Hospital (January 2023-present)

  • Director of Division of Oncology, Taipei Veterans General Hospital (January 2016-present)

  • Director of Labor Safety and Health Office, Taipei Veterans General Hospital (March 2014-January 2016)

  • Director of Medical Affairs, Cancer Center, Taipei Veterans General Hospital (January 2000-March 2014)

  • Director of Radiation Therapy Department, Cancer Center, Taipei Veterans General Hospital (July 1998-January 2000)

  • Attending Physician of Gastroenterology Department, Department of Internal Medicine, Taipei Veterans General Hospital (June 1991-June 1998)

  • Clinical Research Fellow of Gastroenterology Department, Department of Internal Medicine, Taipei Veterans General Hospital (July 1990-June 1991)

  • Physician of Department of Internal Medicine, Taipei Veterans General Hospital (July 1989-June 1990)

  • Chief Physician of Gastroenterology Department, Department of Internal Medicine, Taipei Veterans General Hospital (July 1988-June 1989)

  • Resident Physician of Department of Internal Medicine, Taipei Veterans General Hospital (June 1985-June 1988)

  • Air Force Second Lieutenant Medical Officer (1983-1985)

 

Other Achievements:

  • First Place in Excellent Medical Research Paper Award from Taiwan Cancer Society (2013)

  • Anti-Corruption Role Model from Taipei Veterans General Hospital (2007)

  • First Place in Medical Research Paper Award from Chinese Medical Association (2000)

  • First Place in Physician Academic Research Paper Award from Taipei Veterans General Hospital (1999)

  • Outstanding Clinical Teaching Award from Taipei Veterans General Hospital (1994, 2000)

  • Best Intern at Mackay Memorial Hospital (1983)

 

Selected Publications:

1.       Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Sci Rep. 2021 Jul 28;11(1):15370.

2.       Wu KC, Lee IC, Chi CT, Lei HJ, Chau GY, Yeh YC, Su CW, Huo TI, Chao Y, Lin HC, Hou MC, Huang YH. Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. Am J Cancer Res. 2021 Nov 15;11(11):5526-5542.

3.       Pai SM, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. Front Oncol. 2021 Jun 8;11:632609.

4.       Chen HM, Lin CC, Chen WS, Jiang JK, Yang SH, Chang SC, Ho CL, Yang CC, Huang SC, Chao Y, Liao TT, Hwang WL, Teng HW. Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. Int J Mol Sci. 2021 Jun 28;22(13):6940.

5.       Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer. 2021 Jun;10(3):275-284.

6.       Kang YK, Morita S, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Chen LT, Boku N. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer. 2022 Jan;25(1):207-217.

7.       Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, Chao Y. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer. 2022 Jan 11;22(1):55

8.       Kang YM, Lee YY, Lin SC, Chang FC, Hsu SPC, Lin CF, Liang ML, Chen HH, Wong TT, Lan KL, Chao Y, Chen YW. Bifocal lesions have a poorer treatment outcome than a single lesion in adult patients with intracranial germinoma. PLoS One. 2022 Mar 1;17(3):e0264641.

9.       Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AF, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH, Chao Y. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers (Basel). 2022 Jan 3;14(1):218.

10.    Hsu FT, Tsai CL, Chiang IT, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2022 Feb 17.  Online ahead of print.